ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.62
0.96%
US Tech 100
18,064.80
0.02%
S&P 500
5,277.51
0.80%
US Dollar vs CAD
1.36525
-0.01%
Bitcoin
67,695.15
0.32%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. BridgeBio Pharma Inc (BBIO)

  7. BridgeBio Pharma Inc (BBIO) News

BBIO

BridgeBio Pharma (BBIO)

BridgeBio Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BBIO
DateTimeSourceHeadlineSymbolCompany
05/29/20243:01PMGlobeNewswire Inc.Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NASDAQ:BBIOBridgeBio Pharma Inc
05/24/20246:30AMGlobeNewswire Inc.BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA MeetingNASDAQ:BBIOBridgeBio Pharma Inc
05/17/20243:09PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
05/15/20246:30AMGlobeNewswire Inc.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BBIOBridgeBio Pharma Inc
05/14/20246:30AMGlobeNewswire Inc.BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024NASDAQ:BBIOBridgeBio Pharma Inc
05/13/20246:30AMGlobeNewswire Inc.BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified SensitiNASDAQ:BBIOBridgeBio Pharma Inc
05/02/20246:30AMGlobeNewswire Inc.BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business UpdateNASDAQ:BBIOBridgeBio Pharma Inc
05/02/20246:00AMGlobeNewswire Inc.BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipelineNASDAQ:BBIOBridgeBio Pharma Inc
04/10/20246:30AMGlobeNewswire Inc.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BBIOBridgeBio Pharma Inc
04/07/202412:15PMGlobeNewswire Inc.BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NASDAQ:BBIOBridgeBio Pharma Inc
03/20/20246:30AMGlobeNewswire Inc.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BBIOBridgeBio Pharma Inc
03/06/20244:15PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BBIOBridgeBio Pharma Inc
03/06/20244:13PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
03/05/202410:53PMGlobeNewswire Inc.BridgeBio Pharma Announces Pricing of Public Offering of Common StockNASDAQ:BBIOBridgeBio Pharma Inc
03/04/20244:25PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BBIOBridgeBio Pharma Inc
03/04/20243:17PMGlobeNewswire Inc.BridgeBio Pharma Announces Proposed Public Offering of Common StockNASDAQ:BBIOBridgeBio Pharma Inc
03/04/20246:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
03/04/20241:30AMGlobeNewswire Inc.BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CMNASDAQ:BBIOBridgeBio Pharma Inc
02/22/20243:27PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BBIOBridgeBio Pharma Inc
02/22/20246:31AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
02/22/20246:30AMGlobeNewswire Inc.BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdateNASDAQ:BBIOBridgeBio Pharma Inc
02/21/20243:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
02/20/20243:03PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
02/15/20243:06PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
02/13/20243:05PMEdgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
02/13/20243:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
02/07/20246:34AMGlobeNewswire Inc.BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in JapanNASDAQ:BBIOBridgeBio Pharma Inc
02/06/20246:30AMGlobeNewswire Inc.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BBIOBridgeBio Pharma Inc
02/05/20246:30AMGlobeNewswire Inc.BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NASDAQ:BBIOBridgeBio Pharma Inc
02/02/20246:00AMGlobeNewswire Inc.BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 MonthsNASDAQ:BBIOBridgeBio Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:BBIO

Your Recent History

USOTC
ADMV
Adamas Ventures (GM)
USOTC
BRWC
Birdie Win (PK)
BIT
UB515V
Unicredit Bank
EU
PEF
Invesco Ftse Rafi Europe...
BIT
P1V7L8
NLBNPIT1V7L8 20351221 38...
LSE
FB61
Mitsu Hc Cap.24
ASX
ATRDC
USOTC
MNRLD
Badlands Resources (QB)
USOTC
MTSUY
Mitsubishi (PK)
NASDAQ
EEEE
Educate
BIT
1DEZ
Deutz
LSE
84GQ
Uk Muni Bnd 60
NASDAQ
AAZKGXX
Royal Bank of Canada Cap...
NASDAQ
AAZEEXX
Barclays Bank Plc Autoca...
COIN
HOOKKRW
Hook Token
COIN
TOURRUST
TOUR TOKEN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved